Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?

Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?

Despite maximizing techniques and patient selection, liver resection and ablation for HCC are still associated with high rates of recurrence. To date, HCC is the only cancer with no proven adjuvant or neoadjuvant therapy used in association to potentially curative treatment. Perioperative combinatio...

Full description

Bibliographic Details
Main Authors: Riccardo Nevola, Augusto Delle Femine, Valerio Rosato, Loreta Anesti Kondili, Maria Alfano, Davide Mastrocinque, Simona Imbriani, Pasquale Perillo, Domenico Beccia, Angela Villani, Rachele Ruocco, Livio Criscuolo, Marco La Montagna, Antonio Russo, Aldo Marrone, Ferdinando Carlo Sasso, Raffaele Marfella, Luca Rinaldi, Nicolino Esposito, Giuseppe Barberis, Ernesto Claar
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Cancers
Subjects:
hepatocellular carcinoma
recurrence
adjuvant therapy
neoadjuvant therapy
immunotherapy
immune checkpoint inhibitors
Online Access:https://www.mdpi.com/2072-6694/15/11/2950

Similar Items

Similar Items